Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
C402-CD19-CAR
- Development stage
- Phase 1
- Lead developer
- Exuma Biotechnology
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
C402-CD19-CAR is a rapid Point-Of-Care (rPOC) chimeric antigen receptor T (CAR-T) cell therapy developed by Shanghai Exuma Biotechnology. It is designed to target the CD19 antigen, which is expressed on the surface of most B-cell malignancies. The therapy involves engineering a patient's own T cells to express a CAR that recognizes and binds to CD19, leading to targeted destruction of malignant B cells. The primary indication under investigation for this therapy is relapsed or refractory large B-cell lymphoma[1][2].
- Other names
- C402 CD19 CARC-402 CD19 CARC 402 CD19 CAR
02
Targets
Beyond the preview
Go deeper on C402-CD19-CAR.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on C402-CD19-CAR.